Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/9532
BMPs as therapeutic targets and biomarkers in astrocytic glioma
Biomed Res Int. 2014;2014:549742.
Astrocytic glioma is the most common brain tumor. The glioma initiating cell (GIC) fraction of the tumor is considered as highly chemoresistant, suggesting that GICs are responsible for glioma relapse. A potential treatment for glioma is to induce differentiation of GICs to a more benign and/or druggable cell type. Given BMPs are among the most potent inducers of GIC differentiation, they have been considered as noncytotoxic therapeutic compounds that may be of use to prevent growth and recurrence of glioma. We herein summarize advances made in the understanding of the role of BMP signaling in astrocytic glioma, with a particular emphasis on the effects exerted on GICs. We discuss the prognostic value of BMP signaling components and the implications of BMPs in the differentiation of GICs and in their sensitization to alkylating drugs and oncolytic therapy/chemotherapy. This mechanistic insight may provide new opportunities for therapeutic intervention of brain cancer.
Animals | Astrocytoma | Biomarkers, Tumor | Bone Morphogenetic Proteins | Humans | Neoplasm Proteins | Neoplastic Stem Cells | Prognosis
Files in this item